Actionable news
0
All posts from Actionable news
Actionable news in SRPT: Sarepta Therapeutics, Inc.,

Sarepta shares rise nearly 3% premarket after RBC sees 'compelling' argument for faster approval of DMD drug

Sarepta Therapeutics Inc. SRPT, +1.90% shares surged nearly 3% in premarket trade Monday after RBC Capital Markets analyst Matthew Eckler said he sees a "compelling argument" for faster-than-normal approval of Sarepta's Duchenne muscular dystrophy drug golodirsen. Sarepta recently released positive early/mid-stage clinical trial results for the DMD drug, and presented more data at a conference over the weekend. "Full golodirsen biopsy results look consistent and high-quality; suggest efficacy likely better than Exondys 51," Eckler said, referring to Sarepta's DMD drug that was approved last year after an unusual amount of controversy. Sarepta thus has a "compelling argument for engaging FDA on accelerated approval (meeting likely 1Q18), in our view," Eckler said. Sarepta shares have surged nearly 50% over the last three months, compared with a 5% rise in the S&P 500 SPX, +0.21%


More